Brady W. Dougan - Dec 14, 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Signature
/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Dec 14, 2021
Transactions value $
-$2,729,332
Form type
4
Date filed
12/16/2021, 06:47 PM
Previous filing
Oct 20, 2021
Next filing
May 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$232K -23.7K -2.92% $9.80 786K Dec 14, 2021 Direct F1, F2
transaction HUMA Common Stock Sale -$712K -76.3K -9.7% $9.33 710K Dec 14, 2021 Direct F3
transaction HUMA Common Stock Sale -$1.11M -125K -17.6% $8.89 585K Dec 15, 2021 Direct F4
transaction HUMA Common Stock Sale -$675K -75K -12.82% $9.00 510K Dec 16, 2021 Direct F5
holding HUMA Common Stock 20.5M Dec 14, 2021 By Ayabudge LLC
holding HUMA Common Stock 1.15M Dec 14, 2021 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A portion of this sale is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the purchase by Ayabudge LLC of 1,522,500 shares of the Issuer's common stock on August 26, 2021, at a price per share of $10.00. The Reporting Person has paid the Issuer $71.21, representing the full amount of profit realized in connection with this sale.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.50 to $10.06. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.825 to $9.49. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.68 to $9.43. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $8.79 to $9.33. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.